Argus
•
Apr 22, 2026
APLS: What does Argus have to say about APLS?
Summary
Apellis Pharmaceuticals Inc has an Investment Rating of HOLD; a target price of $43.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subratin
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
CYTK: Lowering target price to $64.00
Apr 29, 2026
•
CYTK
